Several recent large trials just released long term follow-up results on overall survival. We look at what how treatment principles may change based on these mature data.ECHELON-1 - Hodgkin's (A+AVD vs. ABVD)POLO - Pancreatic (olaparib maintenance vs. placebo)Keynote 355 - mTNBC (pembrolizumab + chemo vs. chemo)APHinity - adjuvant HER+ breast (pertuzumab/trastuzumab vs. trastuzumab)E1912 - CLL (ibrutinib/rituximab vs. FCR)